Review ArticleClinical Review

An Evidence-Based and Practical Approach to Using Bydureon™ in Patients With Type 2 Diabetes

Nathan A. Painter, Candis M. Morello, Renu F. Singh and Sarah E. McBane
The Journal of the American Board of Family Medicine March 2013, 26 (2) 203-210; DOI: https://doi.org/10.3122/jabfm.2013.02.120174

References

  1. 1.↵
    Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed January 14, 2013.
  2. 2.↵
    1. Nichols GA,
    2. Kimes TM,
    3. Harp JB,
    4. Kou TD
    . Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes. Diabetes Care 2012;35:495–7.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care 2012; 35 (Suppl 1): S11– 63.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Rodbard HW,
    2. Jellinger PS,
    3. Davidson JA,
    4. et al
    . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540–59.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Drucker DJ,
    2. Nauck MA
    . The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;268:1696–705.
    OpenUrl
  6. 6.↵
    Amylin Pharmaceuticals. Highlights of prescribing information: Bydureon. January 2012. Available from: http://documents.bydureon.com/Bydureon_PI.pdf. Accessed January 14, 2013.
  7. 7.↵
    Amylin Pharmaceuticals. Highlights of prescribing information: Byetta. December 2011. Available from: http://documents.byetta.com/Byetta_PI.pdf. Accessed January 14, 2013.
  8. 8.↵
    Novo Nordisk. Highlights of prescribing information: Victoza. April 2012. Available from: http://www.novo-pi.com/victoza.pdf. Accessed January 14, 2013.
  9. 9.↵
    Merck. Highlights of prescribing information: Januvia. April 2012. Available from: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf. Accessed January 14, 2013.
  10. 10.↵
    Bristol-Myers Squibb. Highlights of prescribing information: Onglyza. December 2011. Available from: http://packageinserts.bms.com/pi/pi_onglyza.pdf. Accessed January 14, 2013.
  11. 11.↵
    Boehringer-Ingelheim International GmBH. Highlights of prescribing information: Tradjenta. September 2012. Available from: http://hcp.tradjenta.com/prescribing-information. Accessed January 14, 2013.
  12. 12.
    1. Rich R
    CPhT. Personal communication. Outpatient Pharmacy Services. University of California, San Diego Medical Center. Cost provided October 9, 2012.
  13. 13.↵
    Alkermes Pharmaceuticals. Fact sheet: Medisorb Microspheres Technology. January 2009. Available from: http://www.biotechinvest.net/uploads/Medisorb.pdf. Accessed January 14, 2013.
  14. 14.↵
    1. DeYoung MB,
    2. MacConell L,
    3. Sarin V,
    4. Trautmann M,
    5. Herbert P
    . Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011;13:1145–54.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Drucker DJ,
    2. Buse JB,
    3. Taylor K,
    4. et al
    ; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240–50.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Blevins T,
    2. Pullman J,
    3. Malloy J,
    4. et al
    . DURA TION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301–10.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Kim D,
    2. MacConell L,
    3. Zhuang D,
    4. et al
    . Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487–93.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Diamant M,
    2. Van Gaal L,
    3. Stranks S,
    4. et al
    . Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234–43.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Buse JB,
    2. Nauck MA,
    3. Forst T,
    4. et al
    . Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6):a randomised, open-label study. Diabetologia 2011; 54 (Suppl 1): A75.
    OpenUrl
  20. 20.↵
    1. Bergenstal RM,
    2. Wysham C,
    3. MacConell L,
    4. et al
    . Efficacy and safety of exenatide once weekly versus sitagliptan or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet 2010;376:431–9.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Russell-Jones D,
    2. Cuddihy RM,
    3. Hanefeld M,
    4. et al
    . Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35:252–8.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Fineman MS,
    2. Mace KF,
    3. Diamant M,
    4. et al
    . Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012;4:546–54.
    OpenUrl
  23. 23.↵
    Amylin Pharmaceuticals. Medication guide: Bydureon. January 2012. Available from: http://documents.bydureon.com/Bydureon_Medication_Guide.pdf. Accessed January 14, 2013.
  24. 24.↵
    Amylin Pharmaceuticals, Inc. Bydureon [homepage]. Available from: http://www.bydureon.com. January 14, 2013.
  25. 25.↵
    1. Lorenzi G,
    2. Schreiner B,
    3. Osther J,
    4. Boardman M
    . Application of adult-learning principles to patient instructions: a usability study for an exenatide once-weekly injection device. Clin Diabetes 2010;28:157–62.
    OpenUrlFREE Full Text
  26. 26.↵
    1. Buse JB,
    2. Drucker DJ,
    3. Taylor KL,
    4. et al
    ; DURATION-1 Study Group. DURATION-1: exenatide once weekly produce sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255–61.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Inzucchi SE,
    2. Bergenstal RM,
    3. Buse JB,
    4. et al
    ; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364– 79.
    OpenUrlFREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords